Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.46USD
9:00pm BST
Change (% chg)

$0.06 (+4.29%)
Prev Close
$1.40
Open
$1.41
Day's High
$1.54
Day's Low
$1.40
Volume
164,318
Avg. Vol
62,418
52-wk High
$4.25
52-wk Low
$1.20

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $66.69
Shares Outstanding(Mil.): 47.64
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 29.57 33.85
EPS (TTM): -0.96 -- --
ROI: -103.73 12.85 12.53
ROE: -110.00 14.07 17.18

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

July 9 A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.

09 Jul 2019

BRIEF-Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US

* ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US

16 Jan 2019

Earnings vs. Estimates